Current Headlines

  1. AI-Powered R&D Acceleration: Insilico Medicine And CMS Announce Multiple Collaborations In Central Nervous System And Autoimmune Diseases 2/10/2026

    Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.

  2. Syngene Collaborates With Johns Hopkins University To Advance Early-Stage Drug Discovery 2/10/2026

    Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early‑stage drug discovery programs and platform technologies emerging from the university’s research labs.

  3. LIGAND-AI Aims To Transform Early Drug Discovery Through Machine Learning 2/10/2026

    A global research initiative that includes researchers from the Leslie Dan Faculty of Pharmacy is undertaking a large-scale project to advance the use of artificial learning (AI) and machine learning to identify small molecules that bind to proteins – an essential first step in early drug discovery.

  4. U.S. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takeda's Oveporexton (TAK-861) As A Potential First-In-Class Therapy For Narcolepsy Type 1 2/10/2026

    Takeda today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1).

  5. NextPoint Therapeutics Announces Clinical Entry Of NPX372, A First-In-Class B7-H7–Targeted T Cell Engager To Treat Solid Tumors 2/9/2026

    NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of NPX372, a first-in-class T cell engager (TCE) for the treatment of patients with solid tumors.

  6. Iambic Announces Collaboration With Takeda To Advance AI-Driven Design Of Small Molecules 2/9/2026

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic’s industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas.

  7. Novartis Breaks Ground On New Global Biomedical Research Center In San Diego To Accelerate Drug Discovery 2/6/2026

    Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients.

  8. IU Drug Discovery Initiative Helps Researchers Move Cancer Drugs From The Lab To Patients 2/5/2026

    An initiative at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center is helping researchers move early-stage drug discoveries from the lab to clinical applications that could transform cancer care and advance progress toward cancer cures.

  9. Biochemists Establish New Method For Identifying Pharmaceutical Candidates Faster 2/5/2026

    A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the lab that could lead to more effective pharmaceuticals.

  10. XtalPi Convenes Global Experts To Shape The Future Of Molecular Glue Drug Discovery: From Serendipity To Precision 2/5/2026

    Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically "undruggable" protein targets.